US › Healthcare

Nanobiotix (NBTX)

US · Healthcare · Biotechnology

$39.52+1.62%

Last close · 2026-08-04

Latest quarter · ended 2025-12-31

Revenue

$3.0M

Revenue YoY

-90.9%

Net profit

$-18.6M

Profit YoY

-60.1%

EPS

$0.00

EPS estimate

$-0.39

Net margin

-618.2%

EPS came in at 0.00 against a street estimate of -0.39 — a beat of 100.0%.

Key statistics

Market cap

$1.95B

Forward P/E

105.3

P/B

65.02

Book value

$-2.00

EPS (TTM)

$-0.57

52-week high

$57.14

52-week low

$6.90

50-day MA

$38.00

200-day MA

$29.79

Beta

0.56

Analyst view

Analysts rate Nanobiotix a strong buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $44.96.

Shareholding

Institutions

11.75%

Largest institutional holders

Fund	Stake
Johnson & Johnson	11.07%
Morgan Stanley - Brokerage Accounts	0.07%
Optiver Holding B.V.	0.03%
Marshall Wace Asset Management Ltd	0.02%
UBS Group AG	0.01%
BNP Paribas Arbitrage, SA	0.01%
Rhumbline Advisers	0.00%
Royal Bank of Canada	0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Nanobiotix — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.